Novozymes to enter new market  

Novozymes plans to produce rheumatoid arthritis treatment under licence

According to TV2 Online, Novozymes is planning to produce the naturally occurring polysaccharide hyaluronic acid for the treatment of rheumatoid arthritis. The market is growing continuously and has an estimated value of DKK 4 billion (USD 480 million). Novozymes will produce the substance under a licence agreement with Hyalose LLC, a privately owned US biotech company headquartered in Oklahoma.


Novozymes currently sells more than 500 enzyme products in 120 countries. Since 1941 Novozymes has introduced almost every new industrial enzyme on the market, and is today the world's largest enzyme manufacturer. The Zealand-based company employs 3,400 people.

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×